Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate therapeutic goods in the Australian market, ensuring their safety, quality, and efficacy. The Act provides the legal framework for the Therapeutic Goods Administration (TGA) to oversee the importation, supply, and advertising of therapeutic goods. This legislation was introduced to address gaps in the regulation of therapeutic goods, aiming to protect public health by ensuring that only safe and quality therapeutic goods are available for use in Australia. In particular, sections 14 and 14A of the Act provide the TGA with the authority to consent to the importation and supply of therapeutic goods that do not fully comply with certain legislative requirements, under specific conditions designed to safeguard public health. The policy objective of this consent, as outlined in the notice issued by a delegate of the Secretary of the Department of Health, was to facilitate the importation and supply of certain pharmaceutical products by Novartis Pharmaceuticals Australia Pty Ltd that do not meet the labelling requirements of Therapeutic Goods Order No. 69, specifically the inclusion of the current sponsor's contact details. This consent, issued on 22 October 2015 and effective until 31 December 2016, was subject to conditions that ensured the continuity of information and support for consumers and healthcare professionals regarding the products in question.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods, which include medicines, medical devices, blood, tissues, and other related products, within Australia. The Act is administered by the Therapeutic Goods Administration (TGA) and is a Commonwealth Act, meaning it applies across the entire nation. The Act encompasses a wide range of entities, including manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as governing the conduct and transactions related to these goods. The Act provides a framework for the regulation of therapeutic goods to ensure their safety, quality, and efficacy. In this context, the Act also allows for specific consents under sections 14 and 14A for certain therapeutic goods that do not fully conform to regulatory requirements, such as labelling specifications, provided that such consents are subject to conditions that mitigate any potential risks to public health and safety. The consent granted to Novartis Pharmaceuticals Australia Pty Ltd for the specified products is an example of such an application, allowing for the import and supply of these products with certain non-conformities in labelling, under strict conditions.

Key Provisions

The Therapeutic Goods Act 1989, under sections 14 and 14A, permits a delegate of the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not conform to specific regulatory requirements. In this instance, Novartis Pharmaceuticals Australia Pty Ltd was granted consent to import and supply certain specified products (sections 14 and 14A). The products listed include various formulations and presentations of ofatumumab, topotecan, trametinib, eltrombopag, dabrafenib, lapatinib, and pazopanib, all of which did not conform to the labelling requirements as stipulated in paragraph 3(2)(l) of Therapeutic Goods Order No. 69. Specifically, the labels did not include the contact details of the current sponsor. The consent granted under sections 14 and 14A of the Act imposes certain obligations on Novartis Pharmaceuticals Australia Pty Ltd. Firstly, the consent requires that the product labels in question were previously approved for the former sponsor, GlaxoSmithKline Australia Pty Ltd. Secondly, it mandates that arrangements are in place with the former sponsor for the prompt referral of any queries or complaints concerning the products to Novartis Pharmaceuticals Australia Pty Ltd. These obligations ensure that despite the non-conformance of the product labels, there is a clear mechanism for addressing any concerns or issues that may arise from the use of these therapeutic goods. Failure to comply with the conditions of the consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989 may result in legal consequences. The Act does not explicitly state the offences or penalties for breaching the conditions of such consent; however, any breach could potentially lead to enforcement actions under the Act. These actions may include, but are not limited to, the suspension or revocation of the consent, fines, or other civil or criminal penalties as deemed appropriate by the relevant authorities. The precise penalties would depend on the nature and severity of the breach, as well as any applicable provisions in other sections of the Act or related regulations.